tetano
Editor, Senior Moderator
Cureus
. 2022 Mar 22;14(3):e23411.
doi: 10.7759/cureus.23411. eCollection 2022 Mar.
Tocilizumab and Baricitinib for Recovery From Acute Exacerbation of Combined Pulmonary Fibrosis and Emphysema Secondary to COVID-19 Infection: A Case Report
Yoshiro Kai[SUP] 1 [/SUP], Masayuki Matsuda[SUP] 1 [/SUP], Kentaro Suzuki[SUP] 1 [/SUP], Takehito Kasamatsu[SUP] 2 [/SUP], Akihiro Kajita[SUP] 2 [/SUP], Kenji Uno[SUP] 2 [/SUP], Shigeo Muro[SUP] 3 [/SUP]
Affiliations
Abstract
Pneumonia secondary to coronavirus disease 2019 (COVID-19) is exacerbated by a disproportionate increase in the systemic inflammatory response and cytokine storm due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Herein, we report the successful treatment of severe COVID-19 pneumonia using a combination of tocilizumab and baricitinib in a patient with combined pulmonary fibrosis and emphysema (CPFE). A 67-year-old male with type 2 diabetes mellitus and CPFE presented with fever and dyspnea and was diagnosed with COVID-19. Upon admission, his respiratory failure was managed using high-flow nasal cannula (HFNC) therapy; however, despite treatment with remdesivir and systemic steroids, his respiratory failure continued to worsen. Therefore, baricitinib was administered from the ninth day of hospitalization for 14 days. Furthermore, his blood interleukin-6 (IL-6) levels showed an increase until day 13. Thus, tocilizumab was administered on the 13th day, which led to symptomatic improvement by day 18. The patient was discharged from our hospital on day 42. This case indicates that combination therapy with tocilizumab and baricitinib improves the efficacy of COVID-19 treatment in patients with comorbidities.
Keywords: acute respiratory failure; baricitinib; covid-19; cpfe; tocilizumab.
. 2022 Mar 22;14(3):e23411.
doi: 10.7759/cureus.23411. eCollection 2022 Mar.
Tocilizumab and Baricitinib for Recovery From Acute Exacerbation of Combined Pulmonary Fibrosis and Emphysema Secondary to COVID-19 Infection: A Case Report
Yoshiro Kai[SUP] 1 [/SUP], Masayuki Matsuda[SUP] 1 [/SUP], Kentaro Suzuki[SUP] 1 [/SUP], Takehito Kasamatsu[SUP] 2 [/SUP], Akihiro Kajita[SUP] 2 [/SUP], Kenji Uno[SUP] 2 [/SUP], Shigeo Muro[SUP] 3 [/SUP]
Affiliations
- PMID: 35481309
- PMCID: PMC9033509
- DOI: 10.7759/cureus.23411
Abstract
Pneumonia secondary to coronavirus disease 2019 (COVID-19) is exacerbated by a disproportionate increase in the systemic inflammatory response and cytokine storm due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Herein, we report the successful treatment of severe COVID-19 pneumonia using a combination of tocilizumab and baricitinib in a patient with combined pulmonary fibrosis and emphysema (CPFE). A 67-year-old male with type 2 diabetes mellitus and CPFE presented with fever and dyspnea and was diagnosed with COVID-19. Upon admission, his respiratory failure was managed using high-flow nasal cannula (HFNC) therapy; however, despite treatment with remdesivir and systemic steroids, his respiratory failure continued to worsen. Therefore, baricitinib was administered from the ninth day of hospitalization for 14 days. Furthermore, his blood interleukin-6 (IL-6) levels showed an increase until day 13. Thus, tocilizumab was administered on the 13th day, which led to symptomatic improvement by day 18. The patient was discharged from our hospital on day 42. This case indicates that combination therapy with tocilizumab and baricitinib improves the efficacy of COVID-19 treatment in patients with comorbidities.
Keywords: acute respiratory failure; baricitinib; covid-19; cpfe; tocilizumab.